摘要
采用酶联免疫吸附法（ELISA）检测了177例癌症（其中食管瘤2例、胃癌12例、肠癌47例、肝癌71例、胆管癌1例、胰腺癌4例、肺癌26例、乳腺癌9例、卵巢癌2例、子宫癌2例、鼻咽癌1例）患言血清可溶性肿瘤坏死因子受体I（sTNFRI）水平。结果显示病人血清中sTNFRI浓度（12904±45．58U／ml）显著高于正常对照组（51．64±26.67U／ml）．P＜0．05，而在各种癌症患者中，肝癌病人的sTNFRI水平为最高（223.07±177．16U／ml）。其结果对了解肿瘤病人的异常免疫状态以及sTNFRI检测的临床价值具有重要意义。
The study was undertaken to detect serum sTNFR I levels in 177 cancer patients (including 2 cases of esophagus cancer. 12 stomach, 1 bile duct, 4 pancreas. 47 colorectum, 71 liver, 26 lung. 9 breast, 2 ovary, 2 uterus and 1 pharyngeas) using sandwich enzyme-linked immune sorbent assay. The results showed that the sTNFR I levels were significantly higher in patients with carcinoma than those in healthy controls. Among all cancer patients, the patients with liver cancer had the highest serum sTNFR I concentration. The correlations between the serum sTNFR I levels and the staging of cancer patients, the other laboratory parameters were also analyzed and discussed. The data indicate that sTNFR I may serve as a marker for abnormal immune status and prognosis of the cancer patients.
出处
《实用肿瘤杂志》
CAS
北大核心
1997年第1期9-11,共3页
Journal of Practical Oncology
基金
广东省自然科学基金
